Heqet Therapeutics
Home - heqettherapeutics
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Website
- heqettherapeutics.com
- Last Round
- Series AMar 2022
- Rounds
- 1
About
Heqet Therapeutics is a pre-clinical stage biotech company focused on the development of non-coding RNA-based therapies to treat cardiovascular diseases, with a specific focus on acute myocardial infarction. The company stems from the groundbreaking research of Prof. Mauro Giacca, Professor of Cardiovascular Sciences at King’s College London. Millions of patients suffer a myocardial infarction every year, and ischemic heart disease remains a leading cause of death worldwide. Heqet is advancing a pipeline of first-in-class compounds for cardiac regeneration to address this unmet clinical need.
Summary
Heqet Therapeutics is a Biotech company, founded in 2021. Its most recent funding was a Series A round in Mar 2022. Investors include Claris Ventures.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Mar 2022
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/heqet-therapeutics"><img src="https://indexed.vc/api/badge/company/heqet-therapeutics" alt="Heqet Therapeutics on Indexed.vc" width="260" height="76" /></a>